CD274 and hepatocellular carcinoma: Currently, clinical trials combining cabozantinib and immune checkpoint inhibitors, including PD-L1 (Trial ID: NCT03755791) and PD-1 (Trial ID: NCT04442581) for HCC treatment, are ongoing.